WO2001066570A1 - Enzyme capable of hydrolyzing plaque, microorganism producing thesame, and a composition comprising the same - Google Patents

Enzyme capable of hydrolyzing plaque, microorganism producing thesame, and a composition comprising the same Download PDF

Info

Publication number
WO2001066570A1
WO2001066570A1 PCT/KR2000/000191 KR0000191W WO0166570A1 WO 2001066570 A1 WO2001066570 A1 WO 2001066570A1 KR 0000191 W KR0000191 W KR 0000191W WO 0166570 A1 WO0166570 A1 WO 0166570A1
Authority
WO
WIPO (PCT)
Prior art keywords
dxamase
enzyme
dextranase
starkeyi
plaque
Prior art date
Application number
PCT/KR2000/000191
Other languages
French (fr)
Korean (ko)
Inventor
Doman Kim
Do-Won Kim
Soo-Jin Heo
Su-Jin Ryu
Original Assignee
Doman Kim
Kim Do Won
Heo Soo Jin
Ryu Su Jin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Doman Kim, Kim Do Won, Heo Soo Jin, Ryu Su Jin filed Critical Doman Kim
Priority to AU33313/00A priority Critical patent/AU3331300A/en
Priority to PCT/KR2000/000191 priority patent/WO2001066570A1/en
Priority to US09/555,535 priority patent/US6485953B1/en
Publication of WO2001066570A1 publication Critical patent/WO2001066570A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2451Glucanases acting on alpha-1,6-glucosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/145Fungal isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/645Fungi ; Processes using fungi

Definitions

  • the present invention relates to an enzyme capable of hydrolyzing
  • dental plaque a microorganism producing the same and a composition comprising the same.
  • Plaque formed on the surface of a tooth is composed of compactly
  • the insoluble glucans are mainly composed of ⁇ -1 ,3-, ⁇ -1 ,4-, ⁇ -
  • amylolytic. and dextranolytic activities are required.
  • S. mutans have been added in oral compositions such as toothpaste or
  • Fluoride is one of the most widely used chemicals because it reduces the growth of S. mutans. Although fluorine can inhibit the growth of the caries inducing bacteria, it can cause caries-like lesions (formation of orthodontic white spots on tooth enamel) as well as severe side effects such as strong toxicity and air pollution. Enzymes such as dextranase have been used to prevent dental caries, however, its effect has yet to be proven.
  • US patent number 5,741 ,773 discloses a toothpaste composition comprising glycomacropeptide having antiplaque and anticaries activities.
  • This invention can prevent the formation of plaque and hydrolyze pre-formed plaque.
  • Another object of the present invention is to provide a microorganism which produces a dental plaque hydrolyzing or inhibiting enzyme.
  • the present invention relates to a dental plaque hydrolyzing or inhibiting enzyme, a preparation method thereof, a composition containing the same and microorganism producing the same.
  • Lipomyces starkeyi (L. starkeyi) produces endo-dextranase (EC 3 2 1 1 1 ) which degrades dextran and ⁇ -amylase which
  • microorganisms are known to be mducible enzymes
  • present inventors are known to be mducible enzymes The present inventors
  • the present invention relates to an enzyme that can inhibit the formation
  • the enzyme of the present invention degrades dextran and starch as
  • DXAMase DXAMase
  • DXAMase according to the present invention mainly produces glucose
  • DXAMase can mainly produce glucose, maltose, maltot ⁇ ose and
  • DXAMase according to the present invention is stable in a variety of mouthwash. Moreover, DXAMase does not lose its enzymatic activity in the presence of by chlorhexidine which is currently used as a remedy of periodontal disease.
  • DXAMase can be isolated from L starkeyi ATCC 74054 or L. starkeyi
  • DXAMase is isolated from a culture medium of L. starkeyi ATCC 74054 or L starkeyi KSM 22, and is identified by double bands of 94K and 60K on a SDS-PAGE (10%) eletrophoresis whose pi is 6.0 for both bands.
  • the present invention also relates to a new microorganism that produces DXAMase.
  • L. starkeyi KSM 22 was obtained by mutating L. starkeyi ATCC 74054 and has a higher productivity of DXAMase than L. starkeyi ATCC 74054.
  • the present microorganism, L. starkeyi KSM 22 has been deposited with Korean Federation of Culture Collections (KFCC) located at Shinchon-dong 134, Seodaemun-ku, Seoul, Korea on Jan. 19, 1999 and was given number KFCC- 11077.
  • KFCC Korean Federation of Culture Collections
  • the same line was also deposited according to the Budapest Treaty at the depository Korean Culture Center of Microorganisms (KCCM) and was given deposit number KCCM-10181 on Mar. 7, 2000.
  • the present invention also relates to a method of producing DXAMase.
  • the method of the present invention comprises culturing L. starkeyi ATCC 74054 or L. starkeyi KSM 22 and recovering DXAMase from the culture medium. Since L starkeyi ATCC 74054 and L starkeyi KSM 22 can produce DXAMase
  • the present invention relates to an anticaries composition
  • composition according to the present invention can be any composition according to the present invention comprising DXAMase.
  • composition according to the present invention can be any composition according to the present invention comprising DXAMase.
  • compositions for oral hygiene such as toothpaste and
  • Dextranase activity is determined by measuring the amount of
  • isomaltose produced by the reaction of an enzyme solution in a buffer solution
  • Dextranase 1 IU is defined as the amount of the enzyme that produces 1 ⁇ mol of isomaltose when reaction is
  • Amylase activity is measured by reacting the enzyme solution in a buffer
  • Minimum salt medium (NH 4 ) 2 S0 4 0.5%(w/v); KH 2 P0 4 0.15%(w/v); MgS0 4 .7H 2 0 0.01%(w/v); NaCI 0.01 %(w/v); CaCI 2 2H 2 0 0.01 %(w/v)
  • LW medium yeast extract 0.3%(w/v); KH 2 P0 4 0.3%(w/v)
  • FIG. 1a is a graphical representation of the effect of pH on relative amylase activity of DXAMase.
  • FIG. 1b is a graphical representation of the effect of pH on relative
  • FIG. 2a is a graphical representation of the effect of temperature on relative amylase activity of DXAMase.
  • FIG. 2b is a graphical representation of the effect of temperature on
  • Figure 3 is a TLC result showing that DXAMase has an ability to degrade
  • Figure 4 is a graphical representation of the prevention of cell aggregation by DXAMase.
  • Figure 5 is a graphical representation of the prevention of plaque
  • Figure 6 is a bar graph representing that DXAMase can remove the pre ⁇
  • Figure 7 is a bar graph representing that DXAMase in mouthwash can
  • Figure 8 is a bar graph representing that DXAMase in mouthwash can
  • Figure 9 is a bar graph representing the stability of DXAMase in a
  • EMS ethylmethanesulfonate
  • sodium thiosulfate 10 %, w.v
  • the upper layer of the two layer agar plate consists of minimum salt medium containingl % starch, 0.05 % 2-deoxy-D-glucose and 1.5 % agar
  • the lower layer consists of blue dextran (0.4% w/v) and 1.5 % agar.
  • L starkeyi KSM 22 was cultured in a 4 L fermentor vessel with LW
  • BIO-RAD A-0.5 column equilibrated with 50 mM citrate phosphate buffer solution (pH 5.5) to perform gel permeation chromatography. The fractions that showed dextranase activity were collected. Two bands at 94 K and 60 K that showed dextranase and amylase activities simultaneously were obtained by performing SDS-PAGE (10 %).
  • the supernatant was separated.
  • One liter of the obtained supernatant was mixed with 1 L of 200 mM sucrose solution prepared with 20 mM phosphate buffer solution (pH 7.0) and incubated for 24 hours before centrifuging to collect the insoluble glucan.
  • the insoluble glucan was suspended in citrate-phosphate buffer solution (20 mM, pH 5.5) at the concentration of 5 mg/mL to prepare an insoluble glucan suspension solution.
  • Example 2 was added and reacted for 48 hours at 37 °C.
  • the reaction product
  • L. starkeyi ATCC 74054 was cultured in 4 L of LW medium containing
  • glucan T2000 dissolved to a concentration of 15 g/mL in 5 mM Tris buffer (pH
  • the absorbance of the mixture was measured at 5-minute intervals for 60 minutes at A 700 .
  • the absorbance decreased as aggregation between cell and soluble glucan T2000 progressed.
  • S. mutans suspension solution was prepared by following the method as in Example 5 except that the cultured and collected cells were suspended at 5 %(wet w/v) in a sterile deionized water.
  • a sterile deionized water To a glass tube, 0.2 mL of cell suspension, 1.0 mL of sucrose solution (concentration of 50 mg/ml dissolved in 100 mM phosphate buffer solution (pH 5.8)), 4.4 mL of sterile deionized water and 0.4 mL DXAMase (equilibrated with 50 mM phosphate buffer solution (pH).
  • attachable material consisting of glucan layers was obtained by using the same method as above except the fact that DXAMase was not added. On these attachable cells, 0.5 lU/mL of DXAMase was added and incubated for 24 hours
  • P. funiculosum dextranase exhibited at least 2 peaks, and these two dextranases did not bind on hydroxyapatite and were eluted by 25 mM phosphate buffer solution.
  • dextranase activity in the case of DXAMase was eluted by 50, 125, 225 mM phosphate buffer solution
  • amylase activity in the case of DXAMase was eluted by 125, 225, 355 mM phosphate buffer solution. From this result, DXAMase is expected to have a higher binding effect on the tooth surface than P. funiculosum dextranase.
  • saliva-coated hydroxyapatite was used to carry out the experiment by loading DXAMase of the present invention.
  • Saliva- coated hydroxyapatite was prepared as follows. After collecting saliva from male and female in their 20's and centrifuging to prepare clear solution, the
  • saliva was mixed with 1 g of hydroxyapatite and incubated for 1 hour. After removing the supernatant by centrifugation and washing with phosphate buffer solution, saliva-coated hydroxyapatite was prepared. DXAMase activity was eluted by using 200-300 mM phosphate buffer solution.
  • Example 2 Into a commercially available mouthwash solution product A(Johnson & Johnson), 5 lU/mL of DXAMase obtained from Example 2 was added. Into a glass tube, 0.2 mL of S. mutans suspension obtained by using the method as in Example 4, 1.0 mL of sucrose solution (dissolved at 50 mg/ml in 100 mM phosphate buffer solution (pH 5.8)), 4.4 mL of sterile deionized water and 0.4 mL DXAMase (50 mM phosphate buffer solution (pH 5.8)) were added and reacted
  • attachable cells wherein glucan layer is formed was obtained by using the same method as above except that DXAMase was not added. On these attachable cells, 1 mL of mouthwash solution containing 5 lU/mL of DXAMase was added and incubated for 24 hours at 37 °C. After carefully removing reaction solution and
  • dextranase activity O amylase activity
  • more than 90 % of initial activity was maintained after 10 months, and more than 73 % of initial activity was maintained after 22 months.
  • a new enzyme that has amylase activity and dextranase activities is provided. Also, the present invention provides an oral composition with an excellent antiplaque and anticaries activities.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a dental plaque hydrolyzing or inhibiting enzyme, a preparation method thereof, a composition containing the same and microorganism producing the same.

Description

ENZYME CAPABLE OF HYDROLYZING PLAQUE, MICROORGANISM
PRODUCING THE SAME AND A COMPOSITION COMPRISING THE SAME
TECHNICAL FIELD
The present invention relates to an enzyme capable of hydrolyzing
dental plaque, a microorganism producing the same and a composition comprising the same.
BACKGROUND OF THE INVENTION
Plaque formed on the surface of a tooth is composed of compactly
packed bacteria and non-cellular materials. The main poiysaccharide
component of plaque is water-insoluble glucan or mutan, which constitutes
approximately 20 % of the dried mass of plaque and is a main cause of dental
caries. Structural studies of glucans produced by Streptococos mutans
revealed that the insoluble glucans are mainly composed of α-1 ,3-, α-1 ,4-, α-
1 ,6-D-glucoside. Therefore, to eliminate plaque effectively, mutanoiytic.
amylolytic. and dextranolytic activities are required.
Conventionally, methods of reducing the growth of Streptococos mutans
(S. mutans) in mouth have been suggested to prevent the formation of plaque or
dental caries. To achieve this, antiseptics or fluoride which inhibit the growth of
S. mutans have been added in oral compositions such as toothpaste or
mouthwash. Fluoride is one of the most widely used chemicals because it reduces the growth of S. mutans. Although fluorine can inhibit the growth of the caries inducing bacteria, it can cause caries-like lesions (formation of orthodontic white spots on tooth enamel) as well as severe side effects such as strong toxicity and air pollution. Enzymes such as dextranase have been used to prevent dental caries, however, its effect has yet to be proven.
US patent number 5,741 ,773 discloses a toothpaste composition comprising glycomacropeptide having antiplaque and anticaries activities.
These conventional techniques relate to the reduction of the bacteria growth that causes dental caries. This invention can prevent the formation of plaque and hydrolyze pre-formed plaque.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide an enzyme which can hydrolyze or inhibit dental plaque.
Another object of the present invention is to provide a microorganism which produces a dental plaque hydrolyzing or inhibiting enzyme.
The present invention relates to a dental plaque hydrolyzing or inhibiting enzyme, a preparation method thereof, a composition containing the same and microorganism producing the same.
DETAILED DESCRIPTION OF THE PRESENT INVENTION
It has been reported that Lipomyces starkeyi (L. starkeyi) produces endo-dextranase (EC 3 2 1 1 1 ) which degrades dextran and α-amylase which
degrades starch This microorganism has been used in food related applications and is not known to produce antibiotics or toxic metabolites
Except for a few bacterial dextranases, dextranases which are produced
by microorganisms are known to be mducible enzymes The present inventors
have reported that L starkeyi ATCC 74054 produces both dextranase and
amylase (US patent 5,229,277) while disclosing the characteristics of the
enzyme produced by the same microorganism The present inventors have
also reported that these microorganisms can produce small molecular weight
dextrans by using sucrose and/or starch
The present invention relates to an enzyme that can inhibit the formation
of or degrade dental plaque
The enzyme of the present invention degrades dextran and starch as
well as insoluble glucans and will be referred to as DXAMase hereinafter
DXAMase according to the present invention mainly produces glucose,
isomaltose and branched tetrose and small amounts of branched pentose and
hexose when dextran is used as a substrate When starch is used as a
substrate, DXAMase can mainly produce glucose, maltose, maltotπose and
maltotetraose as well as a variety of malto-oligosacchaπdes
Since DXAMase can degrade levan which is a polymer of β-fructan,
DXAMase according to the present invention can effectively degrade fructan
forming plaque
DXAMase according to the present invention, therefore, can effectively
degrade soluble as well as insoluble glucans and fructan DXAMase can effectively prevent dental caries since plaque formation can be inhibited by preventing the aggregation of glucan and microorganisms or pre-formed plaque can be eliminated.
Experimental results using hydroxyapatite, which is similar in composition with dental materials, indicate that DXAMase has a stronger binding with hydroxyapatite than P. funiculosum dextranase. Therefore, it is expected that DXAMase will have a higher chance to retain on the tooth surface.
DXAMase according to the present invention is stable in a variety of mouthwash. Moreover, DXAMase does not lose its enzymatic activity in the presence of by chlorhexidine which is currently used as a remedy of periodontal disease.
DXAMase can be isolated from L starkeyi ATCC 74054 or L. starkeyi
KSM 22. In other words, DXAMase is isolated from a culture medium of L. starkeyi ATCC 74054 or L starkeyi KSM 22, and is identified by double bands of 94K and 60K on a SDS-PAGE (10%) eletrophoresis whose pi is 6.0 for both bands.
The present invention also relates to a new microorganism that produces DXAMase. L. starkeyi KSM 22 was obtained by mutating L. starkeyi ATCC 74054 and has a higher productivity of DXAMase than L. starkeyi ATCC 74054. The present microorganism, L. starkeyi KSM 22 has been deposited with Korean Federation of Culture Collections (KFCC) located at Shinchon-dong 134, Seodaemun-ku, Seoul, Korea on Jan. 19, 1999 and was given number KFCC- 11077. The same line was also deposited according to the Budapest Treaty at the depository Korean Culture Center of Microorganisms (KCCM) and was given deposit number KCCM-10181 on Mar. 7, 2000.
The present invention also relates to a method of producing DXAMase. The method of the present invention comprises culturing L. starkeyi ATCC 74054 or L. starkeyi KSM 22 and recovering DXAMase from the culture medium. Since L starkeyi ATCC 74054 and L starkeyi KSM 22 can produce DXAMase
from not only the expensive dextran but also relatively cheap glucose, fructose,
sucrose or starch, it is economical for practical use. DXAMases obtained from
L. starkeyi ATCC 74054 and isolated from L. starkeyi KSM 22 are practically
identical.
Also the present invention relates to an anticaries composition
comprising DXAMase. The composition according to the present invention can
be used as an additive of a composition for oral hygiene such as toothpaste and
mouthwash and food such as candy, chewing gum and beverage. The enzyme
according to the present invention maintains its enzymatic activity for a long
period of time in commercially available mouthwash solutions and has a strong
resistance against enzyme inhibitors. It will be understood that the components
of the oral composition and of food ingredients can be verified without difficulties
within known conventional limits as will be apparent to those skilled in this art.
Definitions
Dextranase activity is determined by measuring the amount of
isomaltose produced by the reaction of an enzyme solution in a buffer solution
containing 2% dextran for 15 min at 37 °C. Dextranase 1 IU is defined as the amount of the enzyme that produces 1 μmol of isomaltose when reaction is
carried out by using dextran as a substrate for 1 min at 37 °C.
Amylase activity is measured by reacting the enzyme solution in a buffer
solution containing 2 % starch for 15 min at 37 °C.
Minimum salt medium: (NH4)2S04 0.5%(w/v); KH2P04 0.15%(w/v); MgS04.7H20 0.01%(w/v); NaCI 0.01 %(w/v); CaCI22H20 0.01 %(w/v)
LW medium: yeast extract 0.3%(w/v); KH2P04 0.3%(w/v)
Glucan hydrolysis rate =
f reducing sugar produced^ f reducing sugar produced ^
Figure imgf000007_0001
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1a is a graphical representation of the effect of pH on relative amylase activity of DXAMase.
FIG. 1b is a graphical representation of the effect of pH on relative
dextranase activity of DXAMase. FIG. 2a is a graphical representation of the effect of temperature on relative amylase activity of DXAMase.
FIG. 2b is a graphical representation of the effect of temperature on
relative dextranase activity of DXAMase.
Figure 3 is a TLC result showing that DXAMase has an ability to degrade
levan.
Figure 4 is a graphical representation of the prevention of cell aggregation by DXAMase.
Figure 5 is a graphical representation of the prevention of plaque
formation as a function of DXAMase concentration.
Figure 6 is a bar graph representing that DXAMase can remove the pre¬
formed plaque.
Figure 7 is a bar graph representing that DXAMase in mouthwash can
prevent glucan formation. Figure 8 is a bar graph representing that DXAMase in mouthwash can
remove the pre-formed insoluble glucan.
Figure 9 is a bar graph representing the stability of DXAMase in a
commercially available mouthwash solution.
Having described the method of this invention, the following figures and
examples will serve to further illustrate the method and describe the best mode
known to the inventors for carrying out the method, but not limited to the
examples given. EXAMPLE 1.
After cultu ng L. starkeyi ATCC 74054 in 1 % solution of minimum salt medium supplemented with 0.5 % dextran and 0.1 % yeast extract for 4 days at
28 °C, the cells were suspended in sterilized 100 mmol"1 phosphate buffered
saline solution (pH 7.0). After treating 1 ml of cell suspension with 100 μl of
ethylmethanesulfonate (EMS) for 5min, 10 min, and 20 min, sodium thiosulfate (10 %, w.v) was added. The upper layer of the two layer agar plate consists of minimum salt medium containingl % starch, 0.05 % 2-deoxy-D-glucose and 1.5 % agar, and the lower layer consists of blue dextran (0.4% w/v) and 1.5 % agar. By observing the degree of formation of transparent circle of blue dextran and performing iodine experiment, a strain that had excellent dextranase as well as amylase activities was selected and named L starkeyi KSM 22.
EXAMPLE 2.
L starkeyi KSM 22 was cultured in a 4 L fermentor vessel with LW
medium (pH 4.0) containing 1 % starch at 30 °C and 100 rpm. After precipitation
of 3 L culture supernatant to 300 ml by adding 70 % ammonium sulfate, the solution was further concentrated to 50 mL by filtering through a 30 K molecular weight cut-off membrane. The concentrated solution was loaded onto a CM- sepharose column equilibrated with 20 mM potassium phosphate buffer solution (pH 6.0) and eluted with 20 mM potassium phosphate buffer solution (pH 6.0) containing 0.5 M NaCI. The fraction that showed dextranase and amylase activities simultaneously was collected and concentrated by adding isopropanol. Three milliliters of the concentrated solution was loaded onto BIO-RAD A-0.5 column equilibrated with 50 mM citrate phosphate buffer solution (pH 5.5) to perform gel permeation chromatography. The fractions that showed dextranase activity were collected. Two bands at 94 K and 60 K that showed dextranase and amylase activities simultaneously were obtained by performing SDS-PAGE (10 %).
Example 3.
The following 50 mM buffer solutions of pH 2.5-7.5 were used to determine the optimum pH of dextranase and amylase activities of the enzyme obtained in Example 2.
Citrate/phosphate buffer solution (pH 2.5~3.5),
Pyridine acetate buffer solution (pH 4.0~5.5), Phosphate buffer solution (pH 6.0-7.5).
The results are shown in Figures 1a and 1b. The stability of dextranase activity and amylase activity as a function of pH was measured after reacting the
enzyme stock for 72 hours at 22 °C at each pH. Dextranase activity was stable
in the pH range of 2.0-7.5 and amylase activity was stable in the pH range of
4.0-6.0.
To determine the optimum temperature range, dextranase activity and amylase activity were measured after reacting for 15 min in a pH 5.5 buffer solution at different temperatures. The results are shown in Figures 2a and 2b. To estimate the temperature stability, the enzyme stock (5 IU) was diluted with a pH 5.5 buffer solution and reacted for 3 min at each temperature before measuring the enzyme activity. At least 80 % of the initial dextranase and
activity were maintained below 50 °C and 80 °C, respectively.
Example 4. Hydrolysis of glucan
Glucosyltransferase isolated from S. mutans was used to prepare the
following insoluble glucan. After culturing S. mutans at 37 °C for 1 day in LW
medium (pH 7.0), the supernatant was separated. One liter of the obtained supernatant was mixed with 1 L of 200 mM sucrose solution prepared with 20 mM phosphate buffer solution (pH 7.0) and incubated for 24 hours before centrifuging to collect the insoluble glucan. The insoluble glucan was suspended in citrate-phosphate buffer solution (20 mM, pH 5.5) at the concentration of 5 mg/mL to prepare an insoluble glucan suspension solution.
Also soluble glucan T-2000 (Pharmacia Co. Sweden) was dissolved in citrate- phosphate buffer solution (20 mM, pH 5.5) at 5 mg/mL to prepare soluble glucan solution. In 1 mL of each glucan sample, 5 IU of enzyme obtained in
Example 2 was added and reacted for 48 hours at 37 °C. The reaction product
was identified by TLC. The result is summarized in Table 1.
L. starkeyi ATCC 74054 was cultured in 4 L of LW medium containing
1 % starch and 0.05 % deoxy-D-glucose at pH 4.0, 30 °C at an aeration of 1.0 ppm for 72 hours. The enzyme was isolated by using an identical method as in Example 2. The above experiment was repeated by using L. starkeyi ATCC 74054. The result is shown in Table 1. The DXAMases produced from Lipomyces starkeyi ATCC 74054 and Lipomyces starkeyi KSM 22 were almost identical.
Also, dextranase (Sigma) produced by Penicillium funiculosum was used to repeat the above experiment. The result is also shown in Table 1.
TABLE 1.
Figure imgf000012_0001
Example 5. Hydrolysis of Levan
Levan, a β-fructan polymer, was dissolved in a citrate-phosphate buffer
solution (20 mM, pH 5.5). DXAMase 11U was added in 100 μL of levan solution
π and incubated for 1 hour before identifying the products by TLC. The result is shown in Figure 3. Since DXAMase according to the present invention can hydrolyze levan, it is expected that DXAMase can effectively degrade fructan that forms plaque.
Example 6. Inhibition of cell aggregation by glucan
The following experiment was performed to observe the cell aggregation by glucan. In 100 mL of tryptic soy broth containing 0.25 % glucose, S. mutans
was inoculated and cultivated overnight at 37 °C. Cells were harvessted by
centrifugation and washed twice with 5 mM Tris buffer (pH 8.4). The washed cells were suspended in an equal volume of identical buffer solution as the
medium. The mixture of 550 μL of cell suspension and 50 μL of water-soluble
glucan T2000 (dissolved to a concentration of 15 g/mL in 5 mM Tris buffer (pH
8.4)) was treated with 50 μL of DXAMase (0.5 lU/ml). After incubating at 40 °C
for 5 min, the absorbance of the mixture was measured at 5-minute intervals for 60 minutes at A700. The absorbance decreased as aggregation between cell and soluble glucan T2000 progressed. When compared to the control without
DXAMase, the degree of aggregation was prohibited by treating with 50 μL of
DXAMase (0.5 lU/ml). The result is shown in Figure 4.
Example 7. Plaque inhibiting and eliminating effect
This experiment was performed by following the method of Schachtele C.F., (Infect. Immun. 1975, 12; 309-317) as follows.
S. mutans suspension solution was prepared by following the method as in Example 5 except that the cultured and collected cells were suspended at 5 %(wet w/v) in a sterile deionized water. To a glass tube, 0.2 mL of cell suspension, 1.0 mL of sucrose solution (concentration of 50 mg/ml dissolved in 100 mM phosphate buffer solution (pH 5.8)), 4.4 mL of sterile deionized water and 0.4 mL DXAMase (equilibrated with 50 mM phosphate buffer solution (pH
5.8)) were added and reacted at 37 °C for 16 - 18 hours without stirring. The
amount of DXAMase was 0 - 2 lU/mL. After carefully removing reaction solution and cells that were not attached, the attached cells were washed with 20 mM phosphate buffer solution (pH 5.8) and suspended by adding 6.0 mL of the identical buffer solution. The turbidity was measured at A550. The result is shown in Figure 5. When compared to the control without DXAMase, 80% of insoluble glucan formation was prohibited by treating with 0.1 lU/mL of DXAMase (Figure 5).
To observe whether DXAMase can eliminate pre-formed glucan layer, attachable material consisting of glucan layers was obtained by using the same method as above except the fact that DXAMase was not added. On these attachable cells, 0.5 lU/mL of DXAMase was added and incubated for 24 hours
at 37 °C. After carefully removing reaction solution and cells that were not
attached, the absorbance was measured at A550 to determine the amount of attachable material. When compared to the control without DXAMase, approximately 80 % of the attachable film was degraded (Figure 6). Example 8. Binding effect on tooth surface
To confirm the binding effect of DXAMase on the tooth surface, the following expeπment was performed. Hydroxyapatite (Bio-Gel HTP, Bio-Rad Laboratories) was suspended in 10 mM phosphate buffer solution (pH 6.8) and packed in a 1.2 x 5 cm column. In each column, 2 mL(10 lU/ml) of P. funiculosum dextranase (Sigma) dissolved in 10 mM KH2P04(pH 6.8) was loaded. Solutions were eluted by using 10mM - 0.5M phosphate buffer solutions (pH 6.8 for all) to collect 1 ml fractions. In each fraction, both dextranase activity and amylase activity were measured. Identical experiment was also carried out by using DXAMase.
P. funiculosum dextranase exhibited at least 2 peaks, and these two dextranases did not bind on hydroxyapatite and were eluted by 25 mM phosphate buffer solution. In contrast, dextranase activity in the case of DXAMase was eluted by 50, 125, 225 mM phosphate buffer solution, and amylase activity in the case of DXAMase was eluted by 125, 225, 355 mM phosphate buffer solution. From this result, DXAMase is expected to have a higher binding effect on the tooth surface than P. funiculosum dextranase.
Instead of hydroxyapatite, saliva-coated hydroxyapatite was used to carry out the experiment by loading DXAMase of the present invention. Saliva- coated hydroxyapatite was prepared as follows. After collecting saliva from male and female in their 20's and centrifuging to prepare clear solution, the
solution was further filtrated (Whatman, 0.2 μm). One milliliter of the prepared
saliva was mixed with 1 g of hydroxyapatite and incubated for 1 hour. After removing the supernatant by centrifugation and washing with phosphate buffer solution, saliva-coated hydroxyapatite was prepared. DXAMase activity was eluted by using 200-300 mM phosphate buffer solution.
Example 9. Plaque inhibiting and eliminating effect (Co-use with mouthwash solution)
Into a commercially available mouthwash solution product A(Johnson & Johnson), 5 lU/mL of DXAMase obtained from Example 2 was added. Into a glass tube, 0.2 mL of S. mutans suspension obtained by using the method as in Example 4, 1.0 mL of sucrose solution (dissolved at 50 mg/ml in 100 mM phosphate buffer solution (pH 5.8)), 4.4 mL of sterile deionized water and 0.4 mL DXAMase (50 mM phosphate buffer solution (pH 5.8)) were added and reacted
at 37 °C for 16 - 18 hours without stirring. After carefully removing reaction
solution and cells that are not attached, the attached cells were washed with 20 mM phosphate buffer solution (pH 5.8) and suspended by adding 6.0 mL of the identical buffer solution. The turbidity was measured at A550. When compared to the control having mouthwash solution without DXAMase, the formation of insoluble glucan with mouthwash solution containing DXAMase was prohibited by 80 %. The result is shown in Figure 7. (1 : sucrose + S. mutans suspension 0.2 mL, 2: sucrose + S. mutans suspension + mouthwash, 3: sucrose + S. mutans + DXAMase, mouthwash).
To evaluate the removable effect of pre-formed glucan layers, attachable cells wherein glucan layer is formed was obtained by using the same method as above except that DXAMase was not added. On these attachable cells, 1 mL of mouthwash solution containing 5 lU/mL of DXAMase was added and incubated for 24 hours at 37 °C. After carefully removing reaction solution and
cells that were not attached, the absorbance was measured at A550 to determine the amount of the attachable material. When compared to the control with mouthwash solution product A without DXAMase, approximately 80 % of the attachable film was degraded. The result is shown in Figure 8.
Example 10. Stability test
To test the stabilization of dextranase and amylase activities of DXAMase by chemicals comprising mouthwash solution, the enzyme activity was measured in the presence of the enzyme inhibitors and chemicals in the mouthwash solutions in Table 2. In 1 mL of each chemical solution, 5 IU of
DXAMase was added and reacted for 5 min at 37 °C. Reaction was further
carried out by adding 2 % dextran or starch of an equal volume. Enzyme activity was measured by using a cupper-bicinchoninate reduction number method (Jeffrey D. Fox et al., Analytical Biochemistry 195, 93-96 (1991)). The result is summarized in Table 2. The enzymatic activity did not decrease by various components comprising the mouthwash or by chlorhexidine, which is mainly used to treat periodontal disease. O 01/66570
Table 2
Figure imgf000018_0001
Example 11.
In 4 different commercially available mouthwash solutions, 10 mg/ml of DXAMase, prepared as in Example 2, was added to observe the stability of the enzyme for a 6 month period. The result is shown in Figure 9. (A: Johnson & Johnson, USA, B: Hanmi Pharmaceutical Co., Korea, C: DongA Pharmaceutical Co., Korea, D: ll-Dong Pharmaceutical Co., Korea). After 6 months, at least
93 % of initial dextranase and amylase activities were maintained. (■:
dextranase activity, O amylase activity). Also, in an A oral composition and a B oral composition, more than 90 % of initial activity was maintained after 10 months, and more than 73 % of initial activity was maintained after 22 months.
According to the present invention, a new enzyme that has amylase activity and dextranase activities is provided. Also, the present invention provides an oral composition with an excellent antiplaque and anticaries activities.

Claims

Claims
1 . An enzyme having antiplaque and anticaries activities, having a molecular
weight of 94 K measured by SDS-PAGE, having dextranase and amylase
activities simultaneously and degrading insoluble glucans.
2. An enzyme having antipiaque and anticaries activities, having a molecular
weight of 60 K estimated by SDS-PAGE, having dextranase and amylase
activities simultaneously and degrading insoluble glucans.
3. The enzyme according to Claim 1 wherein the above enzyme is isolated
from L. starkeyi KSM 22 or L starkeyi ATCC 74054.
4. L. starkeyi KSM 22 (Deposit No. KFCC-1 1077 or KCCM-10181) producing
the enzyme in Claim 1.
5. A preparation method of DXAMase compπsing of culturing L. starkeyi ATCC
74054 or L. starkeyi KSM 22 and recovering DXAMase from the culture
medium.
6. An oral composition comprising one or more enzymes selected from the
group consisting of an enzyme having antiplaque and anticaries activities,
having a molecular weight of 94 K estimated by SDS-PAGE, having
dextranase and amylase activities simultaneously and degrading insoluble
glucans, and an enzyme having antiplaque and anticaries activities, having
a molecular weight of 60 K estimated by SDS-PAGE, having dextranase and
amylase activities simultaneously and degrading insoluble glucans.
PCT/KR2000/000191 1999-03-09 2000-03-09 Enzyme capable of hydrolyzing plaque, microorganism producing thesame, and a composition comprising the same WO2001066570A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU33313/00A AU3331300A (en) 2000-03-09 2000-03-09 Enzyme capable of hydrolyzing plaque, microorganism producing thesame, and a composition comprising the same
PCT/KR2000/000191 WO2001066570A1 (en) 2000-03-09 2000-03-09 Enzyme capable of hydrolyzing plaque, microorganism producing thesame, and a composition comprising the same
US09/555,535 US6485953B1 (en) 1999-03-09 2000-03-09 Enzyme capable of hydorlyzing plaque, microorganism producing the same, and a composition comprising the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2000/000191 WO2001066570A1 (en) 2000-03-09 2000-03-09 Enzyme capable of hydrolyzing plaque, microorganism producing thesame, and a composition comprising the same

Publications (1)

Publication Number Publication Date
WO2001066570A1 true WO2001066570A1 (en) 2001-09-13

Family

ID=19198180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2000/000191 WO2001066570A1 (en) 1999-03-09 2000-03-09 Enzyme capable of hydrolyzing plaque, microorganism producing thesame, and a composition comprising the same

Country Status (2)

Country Link
AU (1) AU3331300A (en)
WO (1) WO2001066570A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018790A1 (en) * 2001-08-25 2003-03-06 Lifenza Co., Ltd. Enzyme with the removal activities of the plaques, dna sequence encoding said enzyme, the expressing host cell and methods for producing and purifying said enzyme
WO2005073368A1 (en) * 2004-01-30 2005-08-11 Lifenza Co., Ltd. Protein with activity of hydrolyzing dextran, starch, mutan, inulin and levan, gene encoding the same, cell expressing the same, and production method thereof
WO2005073369A1 (en) * 2004-01-30 2005-08-11 Lifenza Co., Ltd. Protein with activity of hydrolyzing amylopectin, starch, glycogen and amylose, gene encoding the same, cell expressing the same, and production method thereof
WO2010018167A1 (en) * 2008-08-12 2010-02-18 University Of Copenhagen Dental formulations for the prevention of dental erosion
US8876532B2 (en) 2002-07-31 2014-11-04 Dentsply International Inc. Bone repair putty
CN104207983A (en) * 2014-08-26 2014-12-17 华南理工大学 Denture care solution containing enzyme and pericarpium citri reticulatae extract and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820640A (en) * 1986-03-10 1989-04-11 Louisiana State University And Agriculture And Mechanical College Method of producing dextranase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820640A (en) * 1986-03-10 1989-04-11 Louisiana State University And Agriculture And Mechanical College Method of producing dextranase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEO SOO-JIN ET AL.: "Development of a mixed-culture fermentation process and characterization for new oligosaccharides and dextran using lipomyces starkeyi and leuconostoc mesemteroides", SANOP MISAENGMUL HAKHOECHI, vol. 27, no. 4, 1999, KOREA, pages 304 - 310 *
KIM DOMAN ET AL.: "Characterization of a novel carbohydrase from lipomyces starkeyi KSM 22 for dental application", J. MICROBIOL. BIOTECHNOL., vol. 9, no. 3, 1989, pages 260 - 264, XP002468939 *
RYU SU-JIN ET AL.: "Purification and partial characterization of a novel glucanhydrolase from lipomyces starkeyi KSM22 and its use for inhibition of insoluble glucan formation", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 64, no. 2, 2000, pages 223 - 228, XP003014605, DOI: doi:10.1271/bbb.64.223 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018790A1 (en) * 2001-08-25 2003-03-06 Lifenza Co., Ltd. Enzyme with the removal activities of the plaques, dna sequence encoding said enzyme, the expressing host cell and methods for producing and purifying said enzyme
US8876532B2 (en) 2002-07-31 2014-11-04 Dentsply International Inc. Bone repair putty
WO2005073368A1 (en) * 2004-01-30 2005-08-11 Lifenza Co., Ltd. Protein with activity of hydrolyzing dextran, starch, mutan, inulin and levan, gene encoding the same, cell expressing the same, and production method thereof
WO2005073369A1 (en) * 2004-01-30 2005-08-11 Lifenza Co., Ltd. Protein with activity of hydrolyzing amylopectin, starch, glycogen and amylose, gene encoding the same, cell expressing the same, and production method thereof
WO2010018167A1 (en) * 2008-08-12 2010-02-18 University Of Copenhagen Dental formulations for the prevention of dental erosion
CN104207983A (en) * 2014-08-26 2014-12-17 华南理工大学 Denture care solution containing enzyme and pericarpium citri reticulatae extract and preparation method thereof

Also Published As

Publication number Publication date
AU3331300A (en) 2001-09-17

Similar Documents

Publication Publication Date Title
Pleszczyńska et al. (1→ 3)-α-d-Glucan hydrolases in dental biofilm prevention and control: a review
US4353891A (en) Mutanase
US5527699A (en) Maltohexaose and maltoheptaose-forming amylase from a microorganism
AU2005288314B2 (en) Isocyclomaltooligosaccharide, isocyclomaltooligosaccharide synthase, process for producing them and use thereof
US5102800A (en) Method for preparing novel cyclomaltodextrin gluccanotransferase
JPH09301840A (en) Composition for oral cavity
Sakano et al. Purification and properties of an exo-α-amylase from Pseudomonas stutzeri
Su-Jin et al. Purification and partial characterization of a novel glucanhydrolase from Lipomyces starkeyi KSM 22 and its use for inhibition of insoluble glucan formation
WO2001066570A1 (en) Enzyme capable of hydrolyzing plaque, microorganism producing thesame, and a composition comprising the same
Mahasneh et al. A Medium for Detecting β‐(1→ 3) Glucanase Activity in Bacteria
US6485953B1 (en) Enzyme capable of hydorlyzing plaque, microorganism producing the same, and a composition comprising the same
US5085851A (en) Dental plaque-degrading compositions
KR100358376B1 (en) Dental plaque hydrolyzing enzyme, microorganism producing thereof, and composition containing thereof
KR100809090B1 (en) Protein with the hydrolysis of mutan inulin and levan gene encoding said protein the expressing host cell and methods for producing said protein
KIM et al. Characterization of a novel carbohydrase from Lipomyces starkeyi KSM 22 for dental application
JP3516104B2 (en) Mutanase producing microorganism and mutanase
Kim et al. Glucanhydrolase from Lipomyces starkeyi KSM 22 as potential mouthwash ingredient
JP3516105B2 (en) Mutanase producing microorganism and mutanase
US4159317A (en) Method for preventing alveolar pyorrhea
KOBAYASHI et al. Preparation and some properties of a novel maltotetraose-forming enzyme of Pseudomonas saccharophila
JP2866460B2 (en) Saccharification method of polysaccharide
DK164600B (en) THERMOSTABLE PULLULANASE AND PROCEDURES FOR PREPARING THEREOF AND USING THEREOF IN A PROCEDURE FOR SUPPLYING STARCH OR IN A PROCESS FOR PREPARING MALTOSE WITH HIGH PURITY
KR0130541B1 (en) Novel streptomyces sp which produce glucanase
JP3747083B2 (en) Novel amylase, its production and use
JP3812954B2 (en) Method for producing isomaltosyl fructoside

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09555535

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase